| human | Q5 |
| P6178 | Dimensions author ID | 011773664264.01 |
| P496 | ORCID iD | 0000-0002-8472-617X |
| P10861 | Springer Nature person ID | 011773664264.01 |
| P69 | educated at | University of Buenos Aires | Q194223 |
| P735 | given name | Emilio | Q5371795 |
| Emilio | Q5371795 | ||
| P106 | occupation | researcher | Q1650915 |
| Q49845574 | A century away from the University Reform and beyond football: Does science have social value? |
| Q68645209 | Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats |
| Q78033394 | Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients |
| Q41789038 | Chemiluminescence of ischaemic and reperfused intestine in vivo |
| Q72201830 | Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis |
| Q79333065 | Effect of unilateral superior cervical ganglionectomy on mandibular bone in rats |
| Q46384249 | Erratum to: Taxonomy of rare genetic metabolic bone disorders. |
| Q72938917 | Identifying patients with erythrocyte oxidative stress susceptibility |
| Q30406235 | Impact of alprazolam in allostatic load and neurocognition of patients with anxiety disorders and chronic stress (GEMA): observational study protocol |
| Q46400531 | In vitro and in vivo equivalence studies of alendronate monosodium tablets. |
| Q69853135 | Low level chemiluminescence from isolated rat hepatocytes, intact lung and intestine in situ |
| Q44424648 | Mandible and maxilla bone mineral density and threshold analysis studies by pQCT in two edentulous women receiving pamidronate. |
| Q71141583 | Mineral density gain in vertebrae of osteoporotic women on oral pamidronate reverts a year after treatment discontinuance |
| Q40685102 | Modulation of cytosolic calcium levels in osteoblast-like osteosarcoma cells by olpadronate and its amino-derivative IG-9402. |
| Q81915827 | Olpadronate: a new amino-bisphosphonate for the treatment of medical osteopathies |
| Q72566723 | Oral pamidronate in refractory Paget's disease |
| Q53805783 | Plasma Enalapril Kinetics of Two Modified Formulations Tested in Healthy Volunteers. A Pilot Trial Searching for an Optimum Blood Pressure Control. |
| Q48415833 | Postmarketing trials for rare diseases. |
| Q81503701 | Postmenopausal changes in the distribution of the volumetric BMD of cortical bone. A pQCT study of the human leg |
| Q72795716 | Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile |
| Q70708513 | Protective effects of disodium etidronate and pamidronate against the biomechanical repercussion of betamethasone-induced osteopenia in growing rat femurs |
| Q70953559 | Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover |
| Q86667812 | Should progress in health be always measured in statistical terms? |
| Q80073759 | Skeletal effects of long-term estrogen and testosterone replacement treatment in a man with congenital aromatase deficiency: evidences of a priming effect of estrogen for sex steroids action on bone |
| Q38526438 | Taxonomy of rare genetic metabolic bone disorders. |
| Q70292813 | Thioctic acid in Amanita poisoning |
| Q33414289 | Tolerability of intravenous pamidronate for the treatment of osteoporosis and other metabolic osteopathies: A retrospective analysis |
| Q67255647 | [Bases and applications of the antioxidative properties of thioctic acid] |
| Q57110673 | [Biomedicine philately] |
| Q74498997 | [Clinical application of bisphosphonate's pharmacokinetic principles] |
| Q78022450 | [Clinical importance of fluorine pharmacokinetics] |
| Q69808529 | [Controversy about the H2 blocking action of 1 nocturnal dose of cimetidine in gastric hyperacidity] |
| Q54408072 | [Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients] |
| Q74498983 | [Extended use, up to 6 years, of an oral amino-bisphosphonate in patients with established osteoporosis] |
| Q52902197 | [Morphological studies of hydroxyapatite crystals exposed to disodium pamidronate] |
| Q71795838 | [Osteoporosis: a disease with problems of definition] |
| Q68230055 | [Oxidative cellular damage in the digestive system] |
| Q52333023 | [Pamidronate and olpadronate discoverer, Prof. Olav Maria Leonard Bijvoet passed away]. |
| Q83216053 | [Sexual behavior in patients with schizophrenia: a review of the literature and survey in patients attending a rehabilitation program] |
| Q58847125 | [Thioctic acid in the prevention of the toxic effects of benznidazole] |
| Q74499014 | [Tolerability of oral bisphosponates in patients with osteoporosis and other osteopathies] |
Search more.